Searchable abstracts of presentations at key conferences in endocrinology

ea0026p245 | Pituitary | ECE2011

Efficacy of weekly pegvisomant monotherapy

O'Connor R D , van der Lely A J , Madsen M , Jorgenson J O , Neggers S J C M M

Introduction: Daily administration of Pegvisomant normalizes IGF1 levels >71% of acromegalics (1). Few studies have assessed the efficacy of weekly administration. We assessed the efficacy of weekly pegvisomant for 12 months, after withdrawal of long-acting somatostatin analogs (SSA) in acromegalics previously controlled on combination therapy.Design: Fifteen subjects (8 males), age 58 (35–80) (median (range)) years on combination therapy of hig...

ea0026p7 | Adrenal cortex | ECE2011

Self-management in patients with adrenal insufficiency

van Eck J P , Gobbens R J , Beukers J , Geilvoet W , van der Lely A J , Neggers S J C M M

Objective: The objective of this study was to asses the quality of self-management in patients with primary and secondary adrenal insufficiency and to find patient-related factors that influence quality of self-management.Methods: The quantitative research was assessed by a questionnaire. Mainly focused topics were i) demographic data ii) daily medication intake iii) en route precautions and iv) dose adaptation during medical emergencies. One hundred and...

ea0049gp116 | Endocrine Nursing | ECE2017

Recovery of the hypothalamus-pituitary-adrenal axis after transsphenoidal surgery for pituitary adenomas

van Eck J P , Neggers S J C M M , Janssen J A M J L , de Rijke Y B , Dallenga A H G , Nagtegaal A P , van der Lely A J , Feelders R A

Purpose: Hypopituitarism is frequently associated with lifelong replacement therapy. However, it has been suggested that recovery from hypopituitarism after transsphenoidal surgery (TSS) for pituitary adenomas may occur during follow up. The aim of this study was to assess the frequency of hypothalamus-pituitary-adrenal (HPA) axis recovery after TSS in patients with non-functioning pituitary adenomas and acromegaly.Methods: Over the 3-year observational ...

ea0026p291 | Pituitary | ECE2011

GH receptor mRNA expression and the effect of pegvisomant on GH secretion by somatotroph pituitary adenomas

Neggers S J C M M , Bidlingmaier M , van Koetsveld P M , Feelders R A , Sprij-Mooij D M , de Herder W W , van der Lely A J , Hofland L J

Background: Of the currently available treatment regimes for acromegaly, pegvisomant (PEG-V) has the highest efficacy. During PEG-V treatment, GH serum levels increase. The exact mechanism behind this is remains unclear. It could be explained by an ultra-short feedback loop via GH receptors in the anterior pituitary gland.Objective: To assess the level of GH receptor (GHR) mRNA expression in somatotroph adenomas and to evaluate whether GHR blockade by PE...